Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ADH1B | P00325 | 1/20 | 0.33 |
| ▸ | ADH1C | P00326 | 1/20 | 0.33 |
| ▸ | ADH1A | P07327 | 1/20 | 0.33 |
| ▸ | ADH4 | P08319 | 1/20 | 0.33 |
| ▸ | ADH7 | P40394 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3033972 | 0.94 | TSHR (0.34) | ACE2LMNAADH1BADH1CADH1A | |
| SCHEMBL3024990 | 0.86 | TSHR (0.39) | ACE2LMNAADH1BADH1CADH1A | |
| SCHEMBL51237 | 0.86 | LMNA (0.31) | LMNAADH1BADH1CADH1AADH4 | |
| SCHEMBL3034088 | 0.85 | TSHR (0.37) | TSHR | |
| SCHEMBL3024354 | 0.84 | ADH1B (0.33) | ACE2LMNAADH1BADH1CADH1A | |
| SCHEMBL3024812 | 0.84 | ACE2 (0.44) | ACE2LMNAADH1BADH1CADH1A | |
| SCHEMBL27721174 | 0.82 | ACE2 (0.47) | ACE2ADH1BADH1CADH1AADH4 | |
| Hydrochloric Acid SCHEMBL27961048 | 0.82 | ACE2 (0.43) | ACE2LMNAADH1BADH1CADH1A | |
| SCHEMBL3034938 | 0.82 | ACE2 (0.47) | ACE2ADH1BADH1CADH1AADH4 | |
| SCHEMBL27480469 | 0.82 | ACE2 (0.47) | ACE2ADH1BADH1CADH1AADH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216736-A2 | 2'-CYANOPYRIMIDINE NUCLEOSIDE COMPOUND | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2010-08-26 | — | — | US | disclosed |
| US-20100056466-A1 | 2'-Cyanopyrimidine Nucleoside Compound | MATSUDA, AKIRA (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2045256-A1 | 2'-CYANOPYRIMIDINE NUCLEOSIDE COMPOUND | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 2009-04-08 | — | — | EP | disclosed |
| US-5691319-A | ANTICARCINOGENIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1997-11-25 | — | — | US | disclosed |
| EP-0536936-B1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | SANKYO CO (JP) | 1996-08-14 | — | — | EP | disclosed |
| EP-0536936-A1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | Sankyo Company Limited (JP) | 1993-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216736-A2 | 2'-CYANOPYRIMIDINE NUCLEOSIDE COMPOUND | NUDT1, DPYD, SLC29A1 | ACE2 1401/4885LMNA 1804/4885ADH1B 1955/4885 |
| US-20100056466-A1 | 2'-Cyanopyrimidine Nucleoside Compound | NUDT1, DPYD, SLC29A1 | ACE2 1401/4885LMNA 1804/4885ADH1B 1955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.